Lewis: Regina hospital physician culture is both tragedy and farce
In a bracing 30 pages, including appendices, the report describes a litany of dysfunctions among physicians working in what is supposed to be the most professionally managed precinct of health care. It's not all bleak. There are no allegations of American-style billing for non-existent surgeries or fistfights in the doctors' lounge.
But it is plenty bad enough. The highlights:
Physicians in Regina have largely held themselves apart from the mission, vision and values adopted by the SHA (Saskatchewan Health Authority) since its formation in 2017.
We heard examples of divisions and departments where it appears pursuit of financial compensation has overtaken the priority for high quality accessible care for patients.
There is no functioning electronic health record, and no database that allows either effective wait list management or workforce planning.
The Ministry of Health allows interests to plead their cases directly, undermining the SHA mandated to run the system.
Whether rooted in illness, aging or personality factors, disruptive patterns of behaviour have often been in place for many years and not addressed in a decisive fashion.
Very few physicians were able to describe how they monitor and improve quality in their services.
Leaders who have identified problematic behaviours and acted appropriately to protect patients and teams should not be vilified or suffer retribution.
In some cases, efforts to recruit have been thwarted by physicians to preserve their service volumes despite wait times.
There are legacy contracts, deals and arrangements that create inequity and inconsistency in negotiating with physicians and groups.
It is embarrassing to have to commission a review to make blindingly obvious recommendations. A report on a school system in similar disarray would recommend having principals who are actually in charge. The schools should teach the students to read and write. They should know what students' needs are and organize to meet them. There should be no side deals and special privileges for a few teachers.
Records should be computerized and generate data to plan and assess performance. Evaluate your staff. Discipline teachers who throw tantrums and abuse their colleagues. Is it any wonder why people misbehave when bad behaviour is not only tolerated, but rewarded?
The Regina physicians have told the SHA to park its mission, vision and values where the sun don't shine for eight years, with zero consequence. So much for a unified provincial system. Medical groups have frozen out new recruits to protect their incomes while wait lists ballooned. Physician leaders who tried to impose some order and civility were abused and left hung out to dry.
Don't for a moment think these problems are unique to Regina. Do a quick search of conflict of interest in Alberta, or pediatric chaos in Kelowna. The only difference between Regina and dozens of other communities is that Regina's pathologies are now out in the open.
Like all reports written by physicians about physicians, professional self-governance is assumed to be entirely in the public interest, fully compatible with fulfilling public and professional obligations found routinely unfulfilled, and despite acknowledgement that 'some physicians have lost the plot of why we are here.'
And therein lies the problem. The report says as much: 'Physician autonomy is clashing with the broader social contract to ensure quality and safety.' Workers at Starbucks or Toyota can tell you how their work is organized and monitored to produce quality. Most physicians in Regina are tongue-tied. This is what you get when a profession is accountable to itself, and self-evaluation in a data-free environment is standard operating procedure.
A cultural problem? Sounds so much more anthropological than negligence, cowardice, greed, and abdication of responsibility. As a wise physician friend told me years ago, what you permit, you promote. The rot has been called out. What next?
Steven Lewis spent 45 years as a health policy analyst and health researcher in Saskatchewan. He can be reached at slewistoon1@gmail.com
The Regina Leader-Post has created an Afternoon Headlines newsletter that can be delivered daily to your inbox so you are up to date with the most vital news of the day. Click here to subscribe. With some online platforms blocking access to the journalism upon which you depend, our website is your destination for up-to-the-minute news, so make sure to bookmark leaderpost.com and sign up for our newsletters so we can keep you informed. Click here to subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, July 22, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. "As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives," said Maria Zannes, President and CEO of bioAffinity Technologies. Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking. "We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science," Ms. Zannes said. "Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics." The Canadian patent (Patent No. 3,136,245) – titled "System and Method for Determining Lung Health" – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. About CyPath® Lung CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. View source version on Contacts bioAffinity Technologies Julie Anne OvertonDirector of Communicationsjao@ Investor Relations Dave GentryRedChip Companies Inc.1-800-RED-CHIP (733-2447) or 407-491-4498BIAF@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
an hour ago
- Yahoo
IQVIA beats quarterly estimates on resilient demand for healthcare analytics
(Reuters) -Contract research firm IQVIA Holdings posted second-quarter profit and revenue above Wall Street expectations on Tuesday, as demand rose for its healthcare data and analytics services, sending shares up around 8% in premarket trading. IQVIA's technology and analytics unit, which serves pharmaceutical and consumer health companies, benefited from higher drug approvals by the U.S. Food and Drug Administration. Still, the company narrowed its annual earnings forecast as drugmakers and biotech companies have been cancelling orders given to contract research firms, in response to the U.S. government's drug price negotiation program, proposed federal research budget cuts and potential tariffs. The Trump administration has been considering separate tariffs for the pharmaceutical industry, which could be as high as 200%. But analysts said that, overall, the quarterly results had "more pluses than minuses." "All-in, this print could have been worse and should clear a fairly low bar heading into the quarter," Leerink Partners analyst Michael Cherny said in a note. Quarterly sales at the technology and analytics unit was $1.63 billion, compared with estimates of $1.60 billion, according to data compiled by LSEG. IQVIA's total quarterly revenue rose 5.3% to $4.02 billion, beating analysts' average estimate of $3.96 billion. On an adjusted basis, it reported profit of $2.81 per share for the quarter ending June 30, above expectations of $2.77 per share. IQVIA now expects annual adjusted profit per share between $11.75 and $12.05, compared with $11.70 to $12.10 earlier. The Durham, North Carolina-based company also narrowed its annual revenue expectations to between $16.1 billion and $16.3 billion, from $16 billion to $16.4 billion earlier. The new forecast assumes a roughly $100 million COVID-related impact. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Entrepreneur
an hour ago
- Entrepreneur
From Misdiagnosis to Mission: How One Man's Ordeal Became a Blueprint for Perseverance
What followed was not just a lapse in judgment; it was a decades-long system failure. Dean became the unseen patient. The ignored anomaly. No one had time to read the story. But like any great founder building something against the odds, he—and his tenacious family—refused to give up. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. When Dean Gregorie first developed a small hump below his neck at age sixteen, few paid it any mind. His mother, though, saw more. Weight gain. The round face. The bone-deep fatigue. To her, it spelled something far more complex: Cushing's disease. But when she voiced her concerns, doctors smiled politely and waved them off. "Teenagers gain weight," they said. What followed was not just a lapse in judgment; it was a decades-long system failure. Dean became the unseen patient. The ignored anomaly. No one had time to read the story. But like any great founder building something against the odds, he—and his tenacious family—refused to give up. Seeing What Others Miss The early symptoms were dismissed with lazy diagnoses: poor diet, lack of exercise, and normal adolescence. But Helen Gregorie was relentless. She scoured medical journals. Dug through case studies. Her instincts shouted, "Cushing's." But doctors, operating within conventional playbooks, refused to explore a rare diagnosis. In startup parlance, they ignored the outlier data, clinging to averages instead of curiosity. Dean was a patient who was overlooked not because of ambiguity, but because of predictability. If he had been a product, he would've been shut down in beta without anyone reading the specs. The Burn Cost of Delay Over the next two decades, Dean cycled through over fifty medical professionals. His symptoms worsened: purple striations, skyrocketing blood pressure, relentless fatigue. And yet the narrative never changed. "Lifestyle," they told him. Imagine pitching the same idea to dozens of venture capitalists, each one dismissing it for a reason you know isn't true. Dean wasn't lazy or noncompliant. He was fighting a disease no one bothered to look for. Still, he climbed the corporate ladder in the automotive coatings industry. He earned promotions. He delivered results. But his body was breaking. And behind every workday win, there was a night spent battling exhaustion, shame, and the creeping belief that maybe it really was his fault. A Systemic Breakdown By 2013, his body sent a blunt memo: collapse. Dean landed in the ICU with diabetic ketoacidosis. An endocrinologist was consulted, but not to solve the underlying mystery—just the emergency. Despite glaring signs—signs his family had documented in detail—no one ordered a test for Cushing's. Even after introducing a second endocrinologist, even after infections ravaged his system, even as his skin tore in a workplace fall, nothing changed. It wasn't until 2019 that a single primary care physician broke the inertia. He reviewed his whole history, acknowledged the pattern, and ordered the cortisol tests that would finally unveil the truth: Cushing's disease. Twenty-three years after it all began. Recovery Is Not Linear The tumor was removed in 2020. But there was no triumphant return, no swift rebound. Recovery was glacial. Dean's body, once flooded with cortisol, was suddenly starved of it. Cortisol had to be administered by medication. Energy flatlined. Nights stretched long and restless. Then came the back pain, unrelenting and tied to years of untreated structural damage. "There wasn't a morning I woke up feeling better," Dean says. "There were just mornings I woke up and decided to try again." Sound familiar? Founders know this rhythm. Recovery isn't always exponential growth; it's the grind. The grit. The decision to show up despite the metrics still being red. Turning Pain into Platform This book, Surviving Cushing's Disease: A Young Man's Journey, is Dean's first act of advocacy. Not a TED Talk. Not a foundation. Just this: a deeply personal, unapologetic account of what it means to be invisible in a system designed to treat averages, not anomalies. In its pages, the symptoms of Cushing's—unexplained weight gain, thinning skin, recurrent infections—are given shape and language. Not to diagnose, but to awaken awareness. Dean's story is not a callout. It's a call forward. Startups, Survivors, and Second Opinions Entrepreneurs can draw from Dean's journey as much as patients can: Follow the fringe data : When something feels off—even if others don't see it—pursue it. : When something feels off—even if others don't see it—pursue it. Pressure test the system : Experts are invaluable. But they are not infallible. : Experts are invaluable. But they are not infallible. Leverage the pain: Your hardest chapters may become your most powerful pages. Because sometimes, the most resilient visionaries don't wear lanyards or give keynotes. They survive in silence for years. Then one day, they write. And someone else learns how to speak up. Click here for Amazon Website: